Austar Lifesciences Limited AULSF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -64.03% | -64.45% | -12.41% | -13.66% | 325.97% |
| Total Depreciation and Amortization | 0.88% | -0.30% | -14.23% | -15.46% | -1.26% |
| Total Amortization of Deferred Charges | 2.87% | 1.72% | -2.34% | -3.76% | 13.64% |
| Total Other Non-Cash Items | 624.78% | 618.68% | 32.69% | 30.79% | 2.03% |
| Change in Net Operating Assets | -- | -- | 60.48% | 58.17% | -- |
| Cash from Operations | 140.82% | 138.02% | 19.23% | 17.52% | 99.72% |
| Capital Expenditure | -104.88% | -102.51% | 19.56% | 20.71% | -102.54% |
| Sale of Property, Plant, and Equipment | -- | -- | -88.08% | -88.28% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -114.96% | -114.78% | -35.50% | -36.42% | -52.14% |
| Cash from Investing | -784.94% | -774.56% | -30.63% | -28.74% | -122.35% |
| Total Debt Issued | -39.70% | -39.70% | 43.49% | 43.49% | 11.50% |
| Total Debt Repaid | 9.74% | 9.74% | -22.75% | -22.75% | -0.40% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 30.62% | 30.62% | 7.43% | 7.43% | 25.46% |
| Cash from Financing | -123.44% | -120.84% | 55.88% | 56.51% | 31.69% |
| Foreign Exchange rate Adjustments | -1,880.20% | -1,865.00% | -165.15% | -164.38% | -143.53% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -778.33% | -768.27% | 137.33% | 133.92% | 90.98% |